Meeting Banner
Abstract #2623

Dynamic Contrast-Enhanced MRI to Assess Hepatocellular Carcinoma Response to Transarterial Chemoembolization: a Pilot Study.

Alana Thibodeau-Antonacci1,2, Léonie Petitclerc1,2, Guillaume Gilbert3, Laurent Bilodeau2, Hélène Castel4, Simon Turcotte5, Damien Olivié2, Catherine Huet2, Pierre Perreault2, Gilles Soulez2, An Tang1,2, and Samuel Kadoury1,2,6

1Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 2Radiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 3Philips Healthcare Canada, Markham, ON, Canada, 4Gastroentology and Hepatology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 5Surgery, Hepatopancreatobiliary and Liver Transplantation Division, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, 6Polytechnique Montréal, Montreal, QC, Canada

Hepatocellular carcinoma response to transarterial chemo-embolization is traditionally assessed by qualitative interpretation of imaging features and enhancement dynamics. However, quantitative parameters derived by fitting a dual-input single-compartment model on dynamic contrast-enhanced-MRI data show promise, as they may help discriminate non-viable from viable tumors after treatment. Peak enhancement ratio significantly decreased after transarterial chemo-embolization in tumors with complete response (i.e. non-viable tumor group). This pilot study suggests that quantitative dynamic contrast-enhanced-MRI parameters may be used to assess treatment response.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract